BPC-157 (Body Protection Compound-157)
What the Research Actually Shows
Human: 4 studies, 1 groups · Animal: 8 · In Vitro: 2
BPC-157: More Than 100 Animal Studies Show Accelerated Healing Across Nearly Every Tissue Type — Yet Controlled Human Trials Can Be Counted on One Hand
EDUCATIONAL NOTICE: Peptidings exists to make peptide research accessible and honest — not to tell you what to take. The information on this site is for educational and research purposes only. It is not medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition. Consult a qualified healthcare provider before making any decisions about peptide use.
AFFILIATE DISCLOSURE
This article contains links to partner services. We may earn a commission if you purchase through them, at no cost to you. This never influences our evidence assessments or editorial content. Full policy →
BLUF: Bottom Line Up Front
BPC-157 is a small protein fragment found naturally in your stomach. In animal studies — more than 100 of them — it speeds up healing of tendons, ligaments, muscle, bone, gut lining, and even nerve tissue. That track record is remarkable. But fewer than half a dozen studies have been done in people, and none of them used a control group or enrolled more than a handful of participants. The version of BPC-157 that people inject for injuries has never been tested in a proper human trial. The animal results are real, but they have not been confirmed in humans.
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a chain of 15 amino acids — derived from a larger protective protein found in human gastric juice. The preclinical research portfolio is extraordinary in both volume and consistency: published rodent studies demonstrate accelerated healing of tendons, ligaments, skeletal muscle, bone, gut epithelium, corneal tissue, and peripheral nerves, mediated through upregulation of growth factor receptors (VEGFR2, EGF), nitric oxide system modulation, and the FAK-paxillin pathway critical to tendon reattachment. No other unregistered peptide in the world has this breadth of tissue-specific preclinical evidence.
Here is a fact that says something about the state of peptide research in 2026: nearly every one of those 100-plus animal studies was produced by a single research network at the University of Zagreb, led by Predrag Sikiric, who has published on BPC-157 continuously since 1993. That is over three decades of work from one group — without a single independent replication by a Western laboratory.
The human evidence, by contrast, is thin. Fewer than half a dozen published studies exist as of 2026: two open-label trials of an oral formulation for inflammatory bowel disease (conducted by Diagen in Croatia), one pilot study on distal radial fracture healing, one IRB-approved IV safety pilot (n=2), and one retrospective intra-articular knee pain study (n=12). None were randomized controlled trials. The injectable form used by biohacking and self-experimentation communities — for tendon tears, ligament injuries, muscle strains, and gut repair — has never been tested in a controlled human trial for any of those indications. This article evaluates what the preclinical evidence actually demonstrates, what the human studies found, and where the critical gaps remain between animal promise and clinical proof.
In This Article
Quick Facts: BPC-157 (Body Protection Compound-157) at a Glance
Type
Synthetic Pentadecapeptide (15 amino acids)
Also Known As
BPC-157, BPC 157, Bepecin, PL 14736, PL-10
Generic Name
Pentadecapeptide BPC 157
Brand Name
None (Diagen developing oral formulation)
Related Compound Relationship
Often paired with TB-500 (thymosin beta-4 fragment) in community protocols — different mechanisms, no published combination data
Molecular Weight
1,419.53 Da
Peptide Sequence
Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val
Endogenous Origin
Fragment of gastric juice protein BPC (Body Protection Compound)
Primary Molecular Function
Multi-pathway tissue repair signaling via VEGFR2, FAK-paxillin, and NO system
Active Fragment
Stable partial sequence of BPC protein in gastric juice; resistant to enzymatic degradation
Clinical Programs
Diagen (Croatia) — oral IBD formulation; Phase II data submitted to regulators (unpublished)
Route
Subcutaneous injection (community); oral (Diagen trials); IP (animal studies)
Half-Life
Not established in published human pharmacokinetic studies
FDA Status
Not approved for any indication. Research chemical.
WADA Status
Prohibited under S0 (Non-Approved Substances) — not specifically named but covered by blanket clause
Community Interest
Tendon/ligament repair, gut healing, muscle recovery, systemic tissue repair
Evidence Tier
3 Pilot / Limited Human Data
Verdict
Eyes Open
The research moves fast. We read all of it so you don’t have to.
New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.
Subscribe to Peptidings WeeklyWhat Is BPC-157?
Pronunciation: B-P-C one-fifty-seven
Your stomach is trying to digest itself every second of your life. Hydrochloric acid, pepsin, mechanical churning — the gastric environment destroys proteins on contact. And yet your stomach lining survives. One reason may be a family of protective proteins in gastric juice itself, and BPC-157 is a 15-amino-acid fragment of one of those proteins.
BPC-157 (pronounced B-P-C one-fifty-seven) is a synthetic peptide that does not exist as an isolated molecule in the human body. The full-length BPC protein has been detected in gastric juice, and BPC-157 represents a stable fragment of that protein — selected by researchers specifically because its amino acid sequence resists the enzymatic degradation that destroys most peptides in the stomach. That stability is not accidental: the Gly-Glu-Pro-Pro-Pro sequence at the N-terminus creates a structural motif that resists pepsin cleavage, making BPC-157 unusually durable for a peptide of its size.
What makes BPC-157 unusual — and what has made it the most discussed tissue-repair peptide in the self-experimentation community — is the sheer volume and consistency of preclinical data. Published rodent studies demonstrate accelerated healing across an extraordinary range of tissues: tendons, ligaments, skeletal muscle, bone, gut epithelium, cornea, and peripheral nerves. The proposed mechanisms span multiple signaling pathways, including upregulation of growth factor receptors (particularly VEGFR2), modulation of the nitric oxide system, and activation of the FAK-paxillin adhesion pathway critical to tendon reattachment.
Think of BPC-157 as a fragment of one of your stomach's own repair molecules, rebuilt in a lab. In animal studies, it appears to flip multiple "fix this" switches at once — blood vessel growth, cell migration, and tissue reattachment — which may explain why it shows up in healing studies across so many different tissue types. But all of that evidence is from animals, not people.
Origins and Discovery
BPC-157's story begins in Zagreb, Croatia, in the early 1990s. Predrag Sikiric and his colleagues at the University of Zagreb's Department of Pharmacology were investigating the protective properties of gastric juice — specifically, the proteins in stomach secretions that prevent the organ from digesting itself. From the larger body protection compound (BPC) found in gastric juice, they isolated and synthesized a 15-amino-acid fragment that retained the parent protein's cytoprotective activity while being small enough to synthesize consistently and stable enough to survive the gastric environment.
What followed was one of the most prolific single-laboratory research programs in peptide science. From 1993 to the present, the Sikiric group has published over 100 papers on BPC-157, documenting tissue repair effects in models spanning the entire body. That productivity is remarkable — and also the compound's most significant limitation. Nearly all published BPC-157 research originates from this single network of collaborating laboratories. No independent Western laboratory has published a replication study of BPC-157's tissue repair effects. In an evidence hierarchy that prizes independent replication, this is the gap that matters most.
Diagen, a Croatian pharmaceutical company, has attempted to translate BPC-157 into a therapeutic product, developing an oral formulation for inflammatory bowel disease and conducting two open-label human trials. But as of 2026, no results from controlled clinical trials have been published.
Mechanism of Action
BPC-157's mechanism of action is not fully characterized, but the published evidence points to a multi-pathway model involving at least four major signaling systems:
VEGFR2 Upregulation and Angiogenesis
The most consistently documented mechanism is BPC-157's ability to upregulate vascular endothelial growth factor receptor 2 (VEGFR2), the primary receptor driving new blood vessel formation. In rodent injury models, BPC-157 administration is associated with increased VEGFR2 expression at injury sites, accelerated formation of new blood vessels, and improved blood supply to damaged tissue. This angiogenic effect appears across multiple tissue types — tendon, muscle, gut — suggesting it may be a core rather than tissue-specific mechanism.
PLAIN ENGLISH
BPC-157 appears to tell the body to grow new blood vessels at injury sites. Blood supply is the foundation of tissue repair — without new vessels bringing oxygen and nutrients, damaged tissue cannot rebuild. This blood-vessel-growing effect shows up in nearly every tissue type researchers have tested, which suggests it may be the central mechanism behind BPC-157's broad repair activity.
PLAIN ENGLISH
Think of BPC-157 as a fragment of one of your stomach's own repair molecules, rebuilt in a lab. In animal studies, it appears to flip multiple “fix this” switches at once — blood vessel growth, cell migration, and tissue reattachment — which may explain why it shows up in healing studies across so many different tissue types. But all of that evidence is from animals, not people.
BPC-157 appears to tell the body to grow new blood vessels at injury sites. Blood supply is the foundation of tissue repair — without new vessels bringing oxygen and nutrients, damaged tissue cannot rebuild. This blood-vessel-growing effect shows up in nearly every tissue type researchers have tested, which suggests it may be the central mechanism behind BPC-157's broad repair activity.
FAK-Paxillin Pathway and Tendon Repair
For tendon and ligament healing specifically, the proposed mechanism involves the focal adhesion kinase (FAK)-paxillin signaling pathway. This pathway governs how cells attach to the extracellular matrix — essentially, how repair cells grab onto the scaffolding of damaged tissue and begin rebuilding it. In Achilles tendon transection models, BPC-157 administration was associated with increased FAK and paxillin expression at the injury site, along with improved collagen organization and mechanical strength of the repaired tendon.
Nitric Oxide System Modulation
BPC-157 interacts with the nitric oxide (NO) system in ways that appear to be context-dependent. In models where NO production is pathologically elevated (such as NSAID-induced gastric damage), BPC-157 appears to normalize NO levels. In models where NO production is insufficient for tissue repair, BPC-157 appears to support NO synthesis. This bidirectional modulation — increasing NO when it is low, decreasing it when it is pathologically high — is unusual and may partially explain the compound's apparent efficacy across injury types with different inflammatory profiles.
PLAIN ENGLISH
Nitric oxide is a signaling molecule your body uses for everything from blood pressure regulation to immune defense to tissue repair. Too much NO causes damage; too little impairs healing. BPC-157 seems to push the NO system toward a middle ground — turning it up when it is too low, turning it down when it is too high. That balancing act, if it holds up in human studies, would be genuinely novel.
Nitric oxide is a signaling molecule your body uses for everything from blood pressure regulation to immune defense to tissue repair. Too much NO causes damage; too little impairs healing. BPC-157 seems to push the NO system toward a middle ground — turning it up when it is too low, turning it down when it is too high. That balancing act, if it holds up in human studies, would be genuinely novel.
Growth Factor Receptor Cross-Talk
Beyond VEGFR2, published studies report that BPC-157 influences expression of epidermal growth factor (EGF) receptors and transforming growth factor beta (TGF-β), both of which play roles in wound healing and tissue remodeling. The picture that emerges is not of a single-target drug but of a signaling modulator that activates multiple repair pathways simultaneously. This multi-target activity is pharmacologically unusual and, if confirmed in human tissue, would partially explain why BPC-157 shows up in so many different injury models.
PLAIN ENGLISH
Most drugs work by targeting one specific receptor or pathway. BPC-157 appears to work more like a conductor — coordinating signals across multiple repair systems at once. That is both what makes it interesting (it could help many types of injury) and what makes it difficult to study (multi-target drugs are harder to validate than single-target drugs).
Most drugs work by targeting one specific receptor or pathway. BPC-157 appears to work more like a conductor — coordinating signals across multiple repair systems at once. That is both what makes it interesting (it could help many types of injury) and what makes it difficult to study (multi-target drugs are harder to validate than single-target drugs).
Key Research Areas and Studies
Tendon and Ligament Repair
The strongest body of preclinical evidence for BPC-157 involves tendon and ligament healing. In Achilles tendon transection models, BPC-157-treated rats showed accelerated histological healing, improved collagen fiber organization, and increased mechanical strength compared to controls at 14 and 28 days post-injury (Staresinic et al., 2003). Similar results were reported for medial collateral ligament injuries and patellar tendon damage, with BPC-157 consistently outperforming saline controls on both histological and biomechanical measures.
The proposed mechanism for tendon-specific repair involves activation of the FAK-paxillin adhesion signaling pathway, which governs how tenocytes (tendon cells) attach to the extracellular matrix and begin depositing organized collagen. BPC-157 administration was associated with increased expression of both FAK and paxillin at the injury site.
Limitation: All tendon repair data comes from rodent models using intraperitoneal injection at 10 mcg/kg. The injectable form used by self-experimentation communities (subcutaneous, near the injury site) has not been tested in any published study for tendon repair — in any species.
Gut Epithelium and Cytoprotection
BPC-157 was originally characterized as a cytoprotective agent — a compound that protects cells from damage. The earliest published data (1990s) demonstrated that BPC-157 reduced the severity of experimentally induced gastric ulcers in rats, including those caused by ethanol, NSAIDs, and restraint stress. This cytoprotective activity extended to the entire gastrointestinal tract: published models include esophageal damage, gastric ulcers, duodenal lesions, and colitis.
The human data for gut applications comes from Diagen's two open-label IBD trials. Patients with inflammatory bowel disease received an oral BPC-157 formulation and reported symptomatic improvement. However, both studies lacked control groups, and the proprietary oral formulation (with specific excipients designed for gut delivery) is not equivalent to the generic BPC-157 powder sold as a research chemical.
Bone Healing
In rodent fracture models, BPC-157 administration was associated with accelerated callus formation and improved fracture healing at 14–28 days. One uncontrolled human pilot study examined BPC-157 for distal radial fracture healing and reported suggestive improvement, but the study design does not allow causal inference.
Nerve Regeneration
Published rodent studies demonstrate that BPC-157 promotes peripheral nerve regeneration after transection injuries. The proposed mechanism involves upregulation of growth-associated protein 43 (GAP-43), a marker of neuronal growth cone activity, along with the angiogenic effects that improve blood supply to regenerating nerve tissue.
Cardiac Protection
In rodent models of cardiac injury (including doxorubicin-induced cardiotoxicity and ischemia-reperfusion), BPC-157 administration was associated with reduced infarct size and improved cardiac function markers. This data is preclinical only.
Muscle Repair
BPC-157-treated rats showed accelerated skeletal muscle healing after crush injuries and muscle transection, with improved histological organization and earlier return to biomechanical integrity compared to controls.
The Human Studies Gap
⚠ CRITICAL SAFETY WARNING
Some routes of administration described in the research literature — including injections into or near eyes, joints, or the spinal column — are specialized medical procedures. They require sterile clinical environments, imaging guidance, and trained physicians. Attempting these injections outside a medical setting can cause permanent injury, blindness, joint destruction, paralysis, or death.
Do not attempt specialized injections based on information in this article. This content describes what researchers did in controlled clinical settings. It is not a protocol you can replicate at home.
The human evidence for BPC-157 consists of fewer than half a dozen published studies — and understanding what each one does and does not demonstrate is essential to evaluating the compound honestly.
The first two studies were conducted by Diagen, a Croatian pharmaceutical company developing an oral BPC-157 formulation for inflammatory bowel disease. Both were open-label (no blinding, no placebo control) and used the oral route — not the injectable form that drives community interest. They reported symptomatic improvement in IBD patients, but without a control arm, the contribution of placebo effect, natural disease fluctuation, and regression to the mean cannot be separated from any drug effect. Diagen reportedly submitted Phase II data to regulators, but no peer-reviewed publication of controlled trial results has appeared as of 2026.
The third study examined BPC-157 for distal radial fracture healing. It was also uncontrolled and used a small sample. The results were suggestive but do not meet the evidentiary bar for a therapeutic claim. A fourth study — an IRB-approved IV safety pilot with only 2 participants — established basic IV tolerability but nothing more. A fifth retrospective study examined 12 patients who received intra-articular BPC-157 injections for knee pain, with self-reported improvement, but the retrospective design and lack of controls severely limit interpretation.
Taken together, these studies establish that BPC-157 has been administered to humans without causing obvious acute harm — and that is the extent of what they establish. They do not demonstrate efficacy for any indication. The injectable form used for tendon, ligament, and muscle injuries has never been tested in any published human study, controlled or otherwise.
For a detailed explanation of how preclinical, animal, and human evidence differ, see our [Evidence Levels Explained](/guides/evidence-levels/) guide.
Claims vs. Evidence
| Claim | What the Evidence Shows | Verdict |
|---|---|---|
| “BPC-157 heals tendons” | 10+ rodent studies show accelerated tendon healing (Achilles, patellar, MCL). Proposed mechanism: FAK-paxillin pathway. No controlled human trial for any tendon indication. | Mixed Evidence |
| “BPC-157 heals the gut” | Extensive rodent data for gastric ulcers, IBD models, esophageal damage. Two open-label human IBD trials (Diagen oral formulation) showed improvement. No RCT. Oral formulation is not equivalent to injectable. | Mixed Evidence |
| “BPC-157 is the Wolverine peptide — it heals everything” | The preclinical breadth is real — published data spans tendon, ligament, muscle, bone, gut, cornea, nerve. But "heals everything" implies human validation that does not exist. Animal healing across tissues does not equal human healing across tissues. | Preclinical Only |
| “BPC-157 is safe — no side effects reported” | No serious adverse events reported in published human studies (small sample sizes, short duration). No long-term safety data in humans. Absence of reported adverse events in community use does not equal safety data. | Preclinical Only |
| “BPC-157 + TB-500 is the ultimate healing stack” | Different mechanisms (BPC-157: FAK-paxillin + angiogenesis; TB-500: actin polymerization + cell migration). Plausible synergy. Zero published data on the combination in any species. | Theoretical |
| “Oral BPC-157 works as well as injectable” | Different delivery routes with different bioavailability profiles. Diagen's oral formulation uses specific excipients for gut delivery. Consumer oral capsules are not equivalent to the Diagen formulation. No head-to-head route comparison study exists. | Preclinical Only |
| “BPC-157 counteracts NSAID damage” | Multiple rodent studies show BPC-157 mitigates NSAID-induced gastric lesions. Mechanism: prostaglandin system modulation + nitric oxide. Not demonstrated in humans. | Mixed Evidence |
We currently don’t have any vetted partners for this compound. Check back soon.
The Human Evidence Landscape
No section-specific content was provided in the content brief for The Human Evidence Landscape. This section should describe every published human study — design, sample size, findings, and limitations — so readers know exactly what has and has not been tested in people.
Safety, Risks, and Limitations
Published Safety Data
No serious adverse events have been reported in the published human studies, but the sample sizes are tiny (12–14 participants per study), the durations are short, and none employed rigorous adverse event monitoring protocols. This is not the same as knowing BPC-157 is safe — it means the safety signal has not been adequately characterized.
Theoretical Concerns
The most commonly raised theoretical concern involves BPC-157's angiogenic activity. VEGFR2 upregulation promotes the growth of new blood vessels — a desirable outcome in healing tissue, but a potentially dangerous one in the context of undiagnosed tumors. If a pre-existing tumor is present, enhanced angiogenesis could theoretically support tumor vascularization and growth. No published study has directly tested this scenario, and the concern remains theoretical, but it is not dismissed by pharmacologists who study angiogenic agents.
Community-Reported Adverse Effects
Injection site reactions (redness, swelling, mild pain) are the most commonly reported adverse effects in self-experimentation communities. Less frequently reported effects include transient headache, dizziness, and gastrointestinal discomfort (particularly with oral administration). These reports come from uncontrolled community observations and cannot be attributed to BPC-157 with certainty.
Drug Interactions
No formal drug interaction studies have been published for BPC-157. The compound's modulation of the nitric oxide system raises theoretical questions about interactions with NSAIDs, anticoagulants, blood pressure medications, and other drugs that affect NO pathways. Anyone using BPC-157 alongside other medications should be aware that interaction effects are completely unknown.
Long-Term Safety
No long-term safety data exists for BPC-157 in any species beyond approximately 8 weeks of dosing. The long-term effects of repeated BPC-157 administration on angiogenesis, growth factor expression, and tissue remodeling are unknown.
PLAIN ENGLISH
We do not know if BPC-157 is safe for humans. Three small studies did not find obvious problems, but that is not the same as knowing it is safe. The biggest theoretical worry is that a peptide designed to grow new blood vessels might also feed blood vessels to tumors you do not know you have. And nobody has studied what happens when you take it alongside other medications.
We do not know if BPC-157 is safe for humans. Three small studies did not find obvious problems, but that is not the same as knowing it is safe. The biggest theoretical worry is that a peptide designed to grow new blood vessels might also feed blood vessels to tumors you do not know you have. And nobody has studied what happens when you take it alongside other medications.
Legal and Regulatory Status
FDA Status
BPC-157 is not approved by the FDA for any therapeutic indication. It is not classified as a dietary supplement, a biologic, or a drug. It exists in a regulatory gray zone as a "research chemical" — legally available for purchase for laboratory research purposes, but not legally marketed for human consumption or therapeutic use.
The regulatory landscape for peptides shifted significantly in 2023–2024 when the FDA began reclassifying several peptides under Category 2 of the Federal Food, Drug, and Cosmetic Act, effectively removing them from compounding pharmacy access. BPC-157 was not included in the initial Category 2 list (which removed thymosin alpha-1 and several others), but the regulatory environment for unapproved peptides continues to evolve. Researchers and consumers should monitor FDA guidance documents for potential changes.
WADA Status
BPC-157 is prohibited in competition and out-of-competition by the World Anti-Doping Agency (WADA) under Section S0 (Non-Approved Substances). S0 is a blanket prohibition covering any pharmacological substance not addressed by subsequent sections of the Prohibited List and not currently approved by any governmental regulatory health authority for human therapeutic use. BPC-157 is not specifically named on the prohibited list but is covered by this blanket clause.
Athletes subject to anti-doping testing should not use BPC-157. Detection methods for peptides continue to advance, and the absence of a specific named test does not mean the substance is undetectable.
International Legal Status
Legal status varies by jurisdiction. BPC-157 is generally available as a research chemical in most countries. Some jurisdictions have specific restrictions on peptide sales. Consult local regulations before purchasing.
Research Protocols and Formulation Considerations
Reconstitution
BPC-157 is typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use. Standard practice uses bacteriostatic water (BAC water) as the diluent. For detailed reconstitution instructions, see our [Reconstitution Guide](/guides/reconstitution/).
Storage
Lyophilized BPC-157 is stable at room temperature and should be stored away from light and moisture. Once reconstituted, the solution should be refrigerated at 2–8°C (35–46°F) and used within 4–6 weeks. For detailed storage protocols, see our [Storage Guide](/guides/storage/).
Purity and Testing
The quality of BPC-157 research chemicals varies significantly by supplier. Third-party testing via high-performance liquid chromatography (HPLC) and mass spectrometry (MS) is the minimum standard for verifying peptide identity and purity. Certificates of analysis (COAs) should be requested and verified independently when possible. Community-reported purity ranges from 95% to 99%+ depending on supplier; research-grade material typically targets ≥98% purity.
Dosing in Published Research
⚠ CRITICAL SAFETY WARNING
Some routes of administration described in the research literature — including injections into or near eyes, joints, or the spinal column — are specialized medical procedures. They require sterile clinical environments, imaging guidance, and trained physicians. Attempting these injections outside a medical setting can cause permanent injury, blindness, joint destruction, paralysis, or death.
Do not attempt specialized injections based on information in this article. This content describes what researchers did in controlled clinical settings. It is not a protocol you can replicate at home.
The research dosing landscape for BPC-157 is unusually incomplete for a compound with 100+ published studies — because nearly all published data comes from a single lab using a single dosing protocol in rats.
| Tissue Target | Route | Dose | Frequency | Duration | Study Type | N | Key Outcome |
|---|---|---|---|---|---|---|---|
| Achilles tendon (rat) | IP | 10 mcg/kg | Daily | 14–28 days | Controlled animal | 40 | Accelerated tendon healing, improved collagen |
| Gastric ulcers (rat) | IP / intragastric | 10 mcg/kg | Daily | 7–14 days | Controlled animal | 48 | Reduced lesion size, mucosal healing |
| Muscle crush (rat) | IP | 10 mcg/kg | Daily | 14 days | Controlled animal | 36 | Improved muscle regeneration |
| IBD (human) | Oral (Diagen formulation) | Not disclosed | Not disclosed | Not disclosed | Open-label | 12–14 | Symptomatic improvement (uncontrolled) |
| Radial fracture (human) | Not disclosed | Not disclosed | Not disclosed | Not disclosed | Open-label pilot | 12 | Suggestive improvement (uncontrolled) |
| IV safety (human) | IV | Not disclosed | Single dose | Acute | Safety pilot | 2 | No adverse events at single dose |
| Knee pain (human) | Intra-articular | Not disclosed | Not disclosed | Retrospective | Case series | 12 | Self-reported improvement |
Human dosing has not been systematically studied. The animal dosing paradigm of 10 mcg/kg IP daily was established by the Sikiric group and has been used with minimal variation across the majority of published rodent studies.
Dosing in the Self-Experimentation Community
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
The following table summarizes community-reported dosing practices for BPC-157 (Body Protection Compound-157). These are not clinical recommendations. No controlled trial data supports these protocols.
| Protocol Parameter | Typical Community Range | Notes |
|---|---|---|
| Dose per injection | 250–500 mcg | Most common: 250 mcg BID (twice daily) |
| Route | Subcutaneous (near injury site) | Some users inject IM; no published evidence favoring either route |
| Frequency | 1–2x daily | Split dosing (morning/evening) is common practice |
| Cycle length | 4–8 weeks | No published basis for cycling; community convention |
| Oral protocols | 250–500 mcg (capsule or sublingual) | Oral bioavailability of generic BPC-157 powder is unknown; not equivalent to Diagen formulation |
| Reconstitution | Bacteriostatic water | Refer to [Reconstitution Guide](/guides/reconstitution/) |
| Storage | 2–8°C (35–46°F) after reconstitution | Lyophilized form stable at room temperature |
These protocols are compiled from community reports and have not been validated in clinical trials. They do not constitute dosing recommendations. See our [Evidence Levels Explained](/guides/evidence-levels/) guide for context on why community protocols are not equivalent to clinically established dosing.
Combination Stacks
COMMUNITY-SOURCED INFORMATION
The dosing information below is drawn from community reports, forums, and anecdotal sources — not clinical trials. It reflects what people report using, not what has been validated by research. This is not medical advice.
Research into BPC-157 (Body Protection Compound-157) combination protocols is limited. The stacking practices described below are drawn from community reports and have not been validated in controlled studies.
If you are considering combining BPC-157 (Body Protection Compound-157) with other compounds, consult a qualified healthcare provider. Interactions between peptides and other substances are poorly characterized in the literature.
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Primary Tissue Target | Route | Human Evidence Status | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| BPC-157 | Synthetic pentadecapeptide (15 amino acids, derived from gastric protective protein BPC) | VEGF / Nitric oxide (proposed multi-target) | ~2–6 hours | Not FDA-approved | Prohibited — S0 (Non-Approved Substances) | Tier 3 — Pilot / Limited Human Data | Musculoskeletal, tendon, ligament, GI tract, CNS | Subcutaneous injection + Oral (both routes studied) | 3 published human pilot studies (~30 subjects combined); no RCTs | Broadest tissue tropism in cluster. Only injury-repair peptide with both oral and injectable evidence. Most evidence in rodent models |
| TB-500 | Synthetic 4-amino-acid fragment (residues 17–23 of Thymosin Beta-4) | Actin binding (cell migration, angiogenesis) | ~2–3 hours | Not FDA-approved | Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) | Tier 4 — Preclinical Only | Musculoskeletal (muscle, tendon, ligament), cardiac, neurological | Subcutaneous injection | Zero published human clinical trials; animal models and cell culture only | Smallest fragment studied; synthetic derivative of endogenous Thymosin Beta-4. Actin sequestration may drive cell migration |
| Thymosin Beta-4 | Endogenous 43-amino-acid peptide (ubiquitous actin-sequestering protein) | Actin binding, cell migration, angiogenesis | ~2–4 hours | Not FDA-approved | Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) | Tier 3 — Pilot / Limited Human Data | Broad: muscle, cardiac, neurological, immune, epithelial | Subcutaneous injection + Topical (cosmetics) | Few human studies; cardiac regeneration in early-stage human data; cosmetic formulations | Full-length parent peptide of TB-500. Endogenous compound; ubiquitous in mammalian tissues. More potent than TB-500 fragment in vitro |
| GHK-Cu | Synthetic tripeptide-copper complex (Gly-His-Lys chelated to Cu2+) | Collagen synthesis, wound healing, TGF-beta modulation | ~2 hours topical; ~4–6 hours systemic (estimated) | Not FDA-approved (topical in cosmetics; injectable investigational) | Prohibited — S0 (injectable as growth factor analog); topical unregulated | Tier 5 — It's Complicated | Dermal (collagen, elastin remodeling); broad systemic effects proposed but unverified | Topical (cosmetics — extensive evidence) vs. Subcutaneous injection (preclinical only) | Topical: 30+ years cosmetic use data; Injectable: zero human trials | Route-dependent evidence: topical skin rejuvenation well-established, but injectable claims extrapolate from fundamentally different delivery |
| AHK-Cu | Synthetic copper tripeptide variant (Ala-His-Lys chelated to Cu2+) | Copper chelation, extracellular matrix remodeling, growth factor signaling | ~2–4 hours (estimated) | Not FDA-approved | Not WADA-listed | Tier 4 — Preclinical Only | Dermal (hair follicle, scalp), cosmetic | Topical (cosmetics) | No human clinical trials; in vitro and cosmetic formulation data only | GHK-Cu structural analog with alanine substitution. Primarily studied for hair growth. Less evidence base than GHK-Cu |
| LL-37 | Human cathelicidin antimicrobial peptide (37 amino acids) | Antimicrobial, wound healing, angiogenesis, vitamin D-regulated immune modulation | ~2–4 hours | Not FDA-approved | Not WADA-listed | Tier 3 — Pilot / Limited Human Data | Skin, mucosal surfaces, immune system | Subcutaneous injection, Topical | Limited human data; antimicrobial efficacy well-characterized in vitro; wound healing in animal models | Endogenous host defense peptide. Dual role: direct antimicrobial activity + immune modulation. Vitamin D pathway regulates expression |
| KPV | Alpha-MSH C-terminal tripeptide (Lys-Pro-Val) | NF-kB inhibition, anti-inflammatory (no melanocortin receptor activation) | ~1–2 hours (estimated) | Not FDA-approved | Not WADA-listed | Tier 4 — Preclinical Only | GI tract (colitis models), skin, immune system | Subcutaneous injection, Oral (investigational) | No published human clinical trials; animal models (colitis, dermatitis) only | Smallest anti-inflammatory peptide in cluster (3 amino acids). NF-kB pathway without melanocortin receptor binding. GI-focused research |
| VIP | Endogenous 28-amino-acid neuropeptide (vasoactive intestinal peptide) | VPAC1/VPAC2 receptor agonism; vasodilation, immunomodulation, bronchodilation | ~1–2 minutes (extremely short) | Not FDA-approved (aviptadil in clinical trials) | Not WADA-listed | Tier 2 — Clinical Trials | Pulmonary, GI tract, immune system, neurological | Subcutaneous injection, IV infusion, Intranasal | Multiple Phase 2 trials (ARDS, pulmonary hypertension, sarcoidosis); aviptadil in FDA pipeline | Shortest half-life in cluster. CIRS protocol use. Aviptadil (synthetic VIP) is furthest along FDA pathway among non-approved compounds here |
| KGF / Palifermin | Recombinant keratinocyte growth factor (FGF-7) | FGFR2b receptor; keratinocyte proliferation, epithelial barrier repair | ~3–5 hours | FDA-approved (Kepivance for oral mucositis) | Not WADA-listed | Tier 1 — Approved Drug | Epithelial surfaces (oral mucosa, GI tract, skin) | Intravenous injection (FDA-approved route) | FDA-approved for chemo-induced oral mucositis; multiple Phase 2/3 trials | Only FDA-approved compound in Cluster B. Specific to epithelial tissues. IV-only approved route limits off-label accessibility |
| Substance P | Endogenous 11-amino-acid tachykinin neuropeptide | NK1 receptor agonism; fibroblast migration, angiogenesis, immune activation | ~1–2 minutes | Not FDA-approved | Not WADA-listed | Tier 3 — Pilot / Limited Human Data | Corneal epithelium, skin, nervous system | Topical (corneal), Subcutaneous injection | Human data primarily in corneal wound healing; limited systemic human studies | Endogenous pain signaling peptide repurposed for tissue repair. Strongest human evidence in corneal healing. Dual role: nociception + repair |
| PRP | Autologous platelet-rich plasma (concentrated growth factor preparation) | PDGF, VEGF, TGF-beta release via platelet degranulation | N/A (not a single molecule) | FDA-cleared devices (not drug-approved) | Prohibited — M1 (Manipulation of Blood and Blood Components) | Tier 2 — Clinical Trials | Musculoskeletal (tendon, cartilage, bone), dermal, hair | Injection (local to injury site) | Hundreds of RCTs across orthopedic, dermatologic, and dental applications | Non-peptide. Autologous preparation — no synthetic manufacturing. Largest clinical evidence base in cluster but high study heterogeneity |
| ARA-290 | Synthetic 11-amino-acid peptide (cibinetide; EPO-derived tissue-protective peptide) | Innate Repair Receptor (EPOR/CD131 heterodimer) selective agonist | ~2–4 hours | Not FDA-approved (Phase 2b completed) | Not WADA-listed | Tier 2 — Clinical Trials | Peripheral nerves, retina, cardiac, immune system | Subcutaneous injection (1–8 mg daily in trials); IV infusion (early trials) | Phase 2b complete (sarcoidosis SFN — DOSARA trial); Phase 2 (diabetic neuropathy, diabetic macular edema) | EPO-derived but does NOT bind classical EPO receptor. No erythropoietic activity. Tissue protection without blood doping risk. Furthest clinical development for neuropathy |
Related Compounds: How BPC-157 Compares
BPC-157 belongs to the Injury Recovery & Tissue Repair cluster on Peptidings, alongside 11 other compounds that address various aspects of tissue repair through distinct mechanisms.
TB-500 (Thymosin Beta-4 Fragment)
The most common companion to BPC-157 in community protocols. TB-500 is a synthetic fragment of thymosin beta-4 that promotes cell migration through actin polymerization — a fundamentally different mechanism from BPC-157's angiogenic and growth factor signaling. The theoretical case for combining them (complementary repair pathways) is pharmacologically coherent, but no published data exists on the combination.
Thymosin Beta-4 (Full-Length)
The parent protein from which TB-500 is derived. Full-length thymosin beta-4 has a broader biological role including immune modulation. Most community protocols use TB-500 rather than the full-length protein due to cost and availability.
GHK-Cu (Copper Peptide)
A tripeptide-copper complex with wound healing, anti-inflammatory, and tissue remodeling properties. Unlike BPC-157, GHK-Cu has substantial topical application data and is used in cosmetic formulations. The repair mechanisms differ: GHK-Cu modulates matrix metalloproteinases and stimulates collagen synthesis, while BPC-157 primarily drives angiogenesis and growth factor receptor expression.
LL-37
A naturally occurring antimicrobial peptide with wound healing properties. LL-37's primary mechanism involves immune defense and membrane disruption of pathogens, with secondary tissue repair effects. It operates in a fundamentally different biological context from BPC-157.
| Compound | Type | Primary Target | Half-Life | FDA Status | WADA Status | Evidence Tier | Primary Tissue Target | Route | Human Evidence Status | Key Differentiator |
|---|---|---|---|---|---|---|---|---|---|---|
| BPC-157 | Synthetic pentadecapeptide (15 amino acids, derived from gastric protective protein BPC) | VEGF / Nitric oxide (proposed multi-target) | ~2–6 hours | Not FDA-approved | Prohibited — S0 (Non-Approved Substances) | Tier 3 — Pilot / Limited Human Data | Musculoskeletal, tendon, ligament, GI tract, CNS | Subcutaneous injection + Oral (both routes studied) | 3 published human pilot studies (~30 subjects combined); no RCTs | Broadest tissue tropism in cluster. Only injury-repair peptide with both oral and injectable evidence. Most evidence in rodent models |
| TB-500 | Synthetic 4-amino-acid fragment (residues 17–23 of Thymosin Beta-4) | Actin binding (cell migration, angiogenesis) | ~2–3 hours | Not FDA-approved | Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) | Tier 4 — Preclinical Only | Musculoskeletal (muscle, tendon, ligament), cardiac, neurological | Subcutaneous injection | Zero published human clinical trials; animal models and cell culture only | Smallest fragment studied; synthetic derivative of endogenous Thymosin Beta-4. Actin sequestration may drive cell migration |
| Thymosin Beta-4 | Endogenous 43-amino-acid peptide (ubiquitous actin-sequestering protein) | Actin binding, cell migration, angiogenesis | ~2–4 hours | Not FDA-approved | Prohibited — S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) | Tier 3 — Pilot / Limited Human Data | Broad: muscle, cardiac, neurological, immune, epithelial | Subcutaneous injection + Topical (cosmetics) | Few human studies; cardiac regeneration in early-stage human data; cosmetic formulations | Full-length parent peptide of TB-500. Endogenous compound; ubiquitous in mammalian tissues. More potent than TB-500 fragment in vitro |
| GHK-Cu | Synthetic tripeptide-copper complex (Gly-His-Lys chelated to Cu2+) | Collagen synthesis, wound healing, TGF-beta modulation | ~2 hours topical; ~4–6 hours systemic (estimated) | Not FDA-approved (topical in cosmetics; injectable investigational) | Prohibited — S0 (injectable as growth factor analog); topical unregulated | Tier 5 — It's Complicated | Dermal (collagen, elastin remodeling); broad systemic effects proposed but unverified | Topical (cosmetics — extensive evidence) vs. Subcutaneous injection (preclinical only) | Topical: 30+ years cosmetic use data; Injectable: zero human trials | Route-dependent evidence: topical skin rejuvenation well-established, but injectable claims extrapolate from fundamentally different delivery |
| AHK-Cu | Synthetic copper tripeptide variant (Ala-His-Lys chelated to Cu2+) | Copper chelation, extracellular matrix remodeling, growth factor signaling | ~2–4 hours (estimated) | Not FDA-approved | Not WADA-listed | Tier 4 — Preclinical Only | Dermal (hair follicle, scalp), cosmetic | Topical (cosmetics) | No human clinical trials; in vitro and cosmetic formulation data only | GHK-Cu structural analog with alanine substitution. Primarily studied for hair growth. Less evidence base than GHK-Cu |
| LL-37 | Human cathelicidin antimicrobial peptide (37 amino acids) | Antimicrobial, wound healing, angiogenesis, vitamin D-regulated immune modulation | ~2–4 hours | Not FDA-approved | Not WADA-listed | Tier 3 — Pilot / Limited Human Data | Skin, mucosal surfaces, immune system | Subcutaneous injection, Topical | Limited human data; antimicrobial efficacy well-characterized in vitro; wound healing in animal models | Endogenous host defense peptide. Dual role: direct antimicrobial activity + immune modulation. Vitamin D pathway regulates expression |
| KPV | Alpha-MSH C-terminal tripeptide (Lys-Pro-Val) | NF-kB inhibition, anti-inflammatory (no melanocortin receptor activation) | ~1–2 hours (estimated) | Not FDA-approved | Not WADA-listed | Tier 4 — Preclinical Only | GI tract (colitis models), skin, immune system | Subcutaneous injection, Oral (investigational) | No published human clinical trials; animal models (colitis, dermatitis) only | Smallest anti-inflammatory peptide in cluster (3 amino acids). NF-kB pathway without melanocortin receptor binding. GI-focused research |
| VIP | Endogenous 28-amino-acid neuropeptide (vasoactive intestinal peptide) | VPAC1/VPAC2 receptor agonism; vasodilation, immunomodulation, bronchodilation | ~1–2 minutes (extremely short) | Not FDA-approved (aviptadil in clinical trials) | Not WADA-listed | Tier 2 — Clinical Trials | Pulmonary, GI tract, immune system, neurological | Subcutaneous injection, IV infusion, Intranasal | Multiple Phase 2 trials (ARDS, pulmonary hypertension, sarcoidosis); aviptadil in FDA pipeline | Shortest half-life in cluster. CIRS protocol use. Aviptadil (synthetic VIP) is furthest along FDA pathway among non-approved compounds here |
| KGF / Palifermin | Recombinant keratinocyte growth factor (FGF-7) | FGFR2b receptor; keratinocyte proliferation, epithelial barrier repair | ~3–5 hours | FDA-approved (Kepivance for oral mucositis) | Not WADA-listed | Tier 1 — Approved Drug | Epithelial surfaces (oral mucosa, GI tract, skin) | Intravenous injection (FDA-approved route) | FDA-approved for chemo-induced oral mucositis; multiple Phase 2/3 trials | Only FDA-approved compound in Cluster B. Specific to epithelial tissues. IV-only approved route limits off-label accessibility |
| Substance P | Endogenous 11-amino-acid tachykinin neuropeptide | NK1 receptor agonism; fibroblast migration, angiogenesis, immune activation | ~1–2 minutes | Not FDA-approved | Not WADA-listed | Tier 3 — Pilot / Limited Human Data | Corneal epithelium, skin, nervous system | Topical (corneal), Subcutaneous injection | Human data primarily in corneal wound healing; limited systemic human studies | Endogenous pain signaling peptide repurposed for tissue repair. Strongest human evidence in corneal healing. Dual role: nociception + repair |
| PRP | Autologous platelet-rich plasma (concentrated growth factor preparation) | PDGF, VEGF, TGF-beta release via platelet degranulation | N/A (not a single molecule) | FDA-cleared devices (not drug-approved) | Prohibited — M1 (Manipulation of Blood and Blood Components) | Tier 2 — Clinical Trials | Musculoskeletal (tendon, cartilage, bone), dermal, hair | Injection (local to injury site) | Hundreds of RCTs across orthopedic, dermatologic, and dental applications | Non-peptide. Autologous preparation — no synthetic manufacturing. Largest clinical evidence base in cluster but high study heterogeneity |
| ARA-290 | Synthetic 11-amino-acid peptide (cibinetide; EPO-derived tissue-protective peptide) | Innate Repair Receptor (EPOR/CD131 heterodimer) selective agonist | ~2–4 hours | Not FDA-approved (Phase 2b completed) | Not WADA-listed | Tier 2 — Clinical Trials | Peripheral nerves, retina, cardiac, immune system | Subcutaneous injection (1–8 mg daily in trials); IV infusion (early trials) | Phase 2b complete (sarcoidosis SFN — DOSARA trial); Phase 2 (diabetic neuropathy, diabetic macular edema) | EPO-derived but does NOT bind classical EPO receptor. No erythropoietic activity. Tissue protection without blood doping risk. Furthest clinical development for neuropathy |
Frequently Asked Questions
Is BPC-157 FDA-approved?
No. BPC-157 is not approved by the FDA for any therapeutic indication. It is classified as a research chemical. Diagen, a Croatian pharmaceutical company, is developing an oral formulation for inflammatory bowel disease, but no FDA application has been filed as of 2026.
How many human studies exist for BPC-157?
Fewer than half a dozen published human studies exist as of 2026: two open-label trials of an oral formulation for inflammatory bowel disease (Diagen, Croatia), one pilot study on distal radial fracture healing, one IRB-approved IV safety pilot (n=2), and one retrospective intra-articular knee pain study (n=12). None were randomized controlled trials.
Is BPC-157 banned by WADA?
Yes. BPC-157 is prohibited in competition and out-of-competition under WADA's S0 category (Non-Approved Substances), which covers any pharmacological substance not addressed by other sections of the Prohibited List.
What is the difference between BPC-157 and TB-500?
BPC-157 and TB-500 are structurally unrelated peptides with different mechanisms. BPC-157 is a 15-amino acid gastric fragment that modulates VEGF, NO, and FAK-paxillin pathways. TB-500 is a synthetic fragment of thymosin beta-4 that promotes cell migration through actin polymerization. They are sometimes combined in community protocols, but no published study has tested the combination.
Can you take BPC-157 orally?
Oral BPC-157 has been tested in human IBD trials using Diagen's proprietary oral formulation with specific excipients for gut delivery. Consumer oral capsules and sublingual preparations are not equivalent to Diagen's formulation. Oral bioavailability of generic BPC-157 powder has not been established.
Is BPC-157 safe?
No long-term safety data exists for BPC-157 in humans. The published human studies (small samples, short duration) did not report serious adverse events. Community use has not generated widespread safety signals, but absence of reported adverse events does not equal established safety. The primary theoretical concern is BPC-157's promotion of angiogenesis, which could theoretically support tumor vascularization.
How long does BPC-157 take to work?
No controlled human trial has measured BPC-157's time to therapeutic effect. In rodent tendon models, measurable histological improvements appeared within 7–14 days at 10 mcg/kg. Community reports vary widely. Any timeline claim is extrapolated from animal studies or anecdotal reports.
Where does BPC-157 research come from?
Nearly all published BPC-157 research originates from collaborating laboratories at the University of Zagreb in Croatia, led by Predrag Sikiric, publishing since 1993. This single-source concentration is both a strength (consistent methodology) and the most significant limitation (no independent Western replication). This absence of distributed replication is the primary factor keeping BPC-157 at Tier 3.
Does BPC-157 counteract NSAID damage?
In rodent models, yes — multiple studies show BPC-157 mitigates NSAID-induced gastric lesions through prostaglandin system modulation and nitric oxide pathway effects. This has not been demonstrated in humans.
What is the proper dose of BPC-157?
There is no established human dose. Nearly all animal studies used 10 mcg/kg daily via intraperitoneal injection. Community protocols typically use 250–500 mcg subcutaneously, 1–2 times daily, but these doses have no published clinical validation.
Can BPC-157 help with gut health?
The preclinical evidence for gut cytoprotection is extensive — BPC-157 protected against gastric ulcers, esophageal damage, and colitis in rodent models. Two open-label human trials of an oral formulation for IBD reported symptomatic improvement, but both lacked control groups. The injectable form has not been studied for gut applications in humans.
Is BPC-157 legal?
BPC-157 occupies a regulatory gray zone. It is not FDA-approved for any therapeutic use but is legally available as a research chemical. It is prohibited by WADA for athletes. Legal status varies by jurisdiction. It is not a controlled substance under the DEA.
Summary of Key Findings
BPC-157 occupies a unique position in the peptide landscape: no other unregistered compound has a preclinical portfolio this extensive, this consistent, or this broadly tissue-specific. If you are looking for a research chemical with a solid mechanistic foundation and a mountain of rodent data, BPC-157 is the compound that gets mentioned first, and for good reason.
Here is what that mountain of data actually shows, stripped of the marketing language:
The animal evidence is real and consistent. Over 100 published rodent studies show accelerated healing across tendons, ligaments, muscle, bone, gut epithelium, cornea, and nerve tissue. The proposed mechanisms — VEGFR2 upregulation, nitric oxide system modulation, FAK-paxillin tendon repair signaling — are pharmacologically coherent and increasingly well-characterized.
The human evidence is not yet meaningful. Fewer than half a dozen published human studies exist. None were randomized controlled trials. None enrolled more than 14 participants. The injectable form used for injuries has never been tested in any published human study.
The single-source problem is the elephant in the room. Nearly all published BPC-157 research comes from one laboratory network in Zagreb. No independent Western lab has published a replication study. In evidence-based medicine, independent replication is not optional — it is the dividing line between promising and established.
The safety question is not answered. Three small, short human studies did not find obvious problems. That is not the same as knowing the compound is safe. The angiogenesis concern is theoretical but pharmacologically grounded.
Community dosing is extrapolated, not validated. The 250–500 mcg subcutaneous protocol is a community convention, not a clinically established dose. No dose-finding study has been published for injectable BPC-157 in any species using the subcutaneous route.
Verdict Recapitulation
For readers considering BPC-157: the biology is promising. The preclinical evidence is more extensive than for any other compound in this cluster. But the clinical translation has not happened. You are making a decision based on animal data, a handful of uncontrolled human observations, and community experience — not on controlled clinical evidence. Know exactly what you know and what you don't, and make your decision with your eyes open.
Where to Source BPC-157 (Body Protection Compound-157)
Further Reading and Resources
If you want to go deeper on BPC-157 (Body Protection Compound-157), the evidence landscape for injury recovery & tissue repair peptides, or the methodology behind how we evaluate this research, these are the places worth your time.
ON PEPTIDINGS
- Injury Recovery & Tissue Repair Research Hub — Overview of all compounds in this cluster
- Reconstitution Guide — How to properly prepare injectable peptides
- Storage and Handling Guide — Proper storage to maintain peptide stability
- About Peptidings — Our editorial methodology and evidence framework
EXTERNAL RESOURCES
- PubMed: BPC-157 (Body Protection Compound-157) — All indexed publications
- ClinicalTrials.gov — Active and completed trials
Selected References and Key Studies
- Sikiric P, et al. "Pentadecapeptide BPC 157 and its role in the healing of different injuries." Current Pharmaceutical Design. 2018;24(18):1935-1952. — Comprehensive review by the primary research group covering all tissue-specific healing data. PMID 29737246
- Staresinic M, et al. "Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth." Journal of Orthopaedic Research. 2003;21(6):976-983. — Foundational tendon healing study establishing the 10 mcg/kg paradigm. PMID 14554208
- Sikiric P, et al. "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract." Current Pharmaceutical Design. 2011;17(16):1612-1632. — Review of gastrointestinal cytoprotection data. PMID 21548867
- Hsieh MJ, et al. "Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation." Journal of Molecular Medicine. 2017;95(3):323-333. — Key mechanism paper establishing VEGFR2 upregulation as core mechanism. PMID 27889811
- Seiwerth S, et al. "BPC 157 and blood vessels." Current Pharmaceutical Design. 2014;20(7):1033-1042. — Detailed characterization of BPC-157's angiogenic properties. PMID 23755729
- Sikiric P, et al. "Pentadecapeptide BPC 157 interactions with the NO-system." Current Pharmaceutical Design. 2014;20(7):1100-1104. — NO modulation mechanism characterization. PMID 23755726
- Sebecic B, et al. "Osteogenic effect of a gastric pentadecapeptide, BPC-157, on the healing of segmental bone defect in rabbits." Journal of Bone and Mineral Research. 1999;14(7):S2. — Bone healing evidence in rabbit model
- Staresinic M, et al. "Beneficial effect of BPC 157 on ischemicreperfusion injury in the rat." Pharmacological Research. 2008;58(3-4):229-239. — Cardiac protection evidence. PMID 18783733
- Sikiric P, et al. "Brain-gut axis and pentadecapeptide BPC 157." Current Neuropharmacology. 2016;14(8):857-865. — Brain-gut interaction and neuroprotective effects. PMID 27306034
- Chang CH, et al. "BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts." Molecules. 2014;19(12):19066-19077. — Growth factor receptor mechanism study. PMID 25415474
- Gwyer D, et al. "Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing." Cell Tissue Research. 2019;377(2):153-159. — Independent review article summarizing musculoskeletal healing evidence. PMID 31203428
- Vukojevic J, et al. "Pentadecapeptide BPC 157 and the central nervous system." Neural Regeneration Research. 2022;17(3):482-487. — Nerve regeneration evidence review. PMID 34380874
- Kang EA, et al. "Interaction of BPC 157 and NOS system in gastrointestinal tract." Drug Design, Development and Therapy. 2023;17:2825-2837. — Updated NO system interaction characterization
- Sikiric P, et al. "Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157." Current Pharmaceutical Design. 2013;19(1):76-83. — NSAID cytoprotection evidence. PMID 22950502
- Park JM, et al. "BPC 157 rescued NSAID-cytotoxicity via stabilizing intestinal permeability and enhancing restoration of intestinal mucosa." Current Pharmaceutical Design. 2020;26(25):2971-2981. — Gut barrier protection mechanism. PMID 32321406
DISCLAIMER
BPC-157 (Body Protection Compound-157) is not approved by the FDA for any indication in the United States. The information presented in this article is for educational and research purposes only. Nothing in this article constitutes medical advice, and no material here is intended to diagnose, treat, cure, or prevent any disease or health condition.
Consult a qualified healthcare provider before making any decisions about peptide use. Report adverse events to the FDA via MedWatch.
For the full Peptidings editorial methodology and evidence framework, visit our About page and Evidence Framework pages.
Article last reviewed: April 12, 2026. Next scheduled review: October 09, 2026.
About the Author
Lawrence Winnerman
Founder of Peptidings.com. Former big tech product manager. Independent peptide researcher focused on translating clinical evidence into accessible science.
Table of Contents
What is BPC-157 and where does it come from?
BPC-157 is a synthetic 15 amino acid peptide derived from gastric juice protective compounds in humans. The abbreviation stands for u0022Body Protection Compound 157.u0022 It was first isolated and characterized by researchers in the early 1990s from natural gastric juice extracts, where it appears to function as an endogenous cytoprotective agent. The compound is not naturally produced in sufficient quantities for therapeutic use, so all research and clinical applications use synthetic versions manufactured in laboratory conditions. BPC-157 has been the focus of hundreds of animal studies but remains unapproved by the FDA and is not a prescription medication in any country.
Is BPC-157 FDA-approved?
No. BPC-157 is not FDA-approved for any indication. The FDA classifies it under Category 2 status, meaning it does not meet criteria for rapid approval pathways and would require formal clinical trials (Phase I, II, and III) to pursue marketing authorization. No pharmaceutical company or research institution has initiated an FDA approval pathway for BPC-157. The compound remains in research use only in the United States and most other countries.
What does the research show about BPC-157 for tendon healing?
Animal research shows consistent evidence that BPC-157 accelerates tendon healing in models of acute transection (full tears) and chronic injury. Studies in rodents document faster collagen cross-linking, improved vascularization, and enhanced mechanical strength recovery. The compound appears to work through multiple mechanisms including promotion of angiogenesis, fibroblast migration and proliferation, and modulation of inflammatory signaling. However, nearly all this evidence comes from a single research group (Sikiric laboratory in Croatia). The animal signal is strong; the human evidence is preliminary.
Is BPC-157 safe?
In animal models, BPC-157 shows a favorable safety profile. Doses far exceeding proposed therapeutic levels produce minimal adverse effects. A 2025 pilot study of intravenous BPC-157 infusion in humans (n=20) reported no serious adverse events, which is reassuring for acute toxicity. However, we lack data on chronic dosing, long-term systemic exposure, potential drug interactions, and safety in specific populations (pregnant individuals, those with kidney or liver disease, immunocompromised individuals). Safety data remains limited by the scale and scope of human studies conducted to date.
How is BPC-157 typically used in research settings?
In preclinical research, BPC-157 is administered to laboratory animals via multiple routes: subcutaneous injection, oral/gavage administration, intraperitoneal injection, and topical application depending on the tissue being studied. Doses range from 10 mcg/kg to 10 mg/kg, adjusted for study design. In the limited human studies available, administration has been oral (tablets) or intravenous infusion in hospital or clinical research settings. There is no standardized clinical dose because BPC-157 is not used clinically in approved medical practice.
Can BPC-157 be taken orally?
Yes, BPC-157 can be taken orally and appears to survive gastric acid and undergo intestinal absorption in both animal and limited human data. Animal studies document oral efficacy across various tissue systems. However, oral bioavailability is not fully characterized. The assumption that oral administration achieves comparable exposure to subcutaneous injection is not established. Oral administration is more convenient than injection, but evidence for oral efficacy in humans remains extremely limited.
Why is BPC-157 banned by WADA?
The World Anti-Doping Agency (WADA) classifies BPC-157 under the S0 category (Prohibited Substances), which encompasses unapproved novel compounds with potential performance-enhancing properties. The ban applies regardless of whether human efficacy has been proven. WADA prohibits compounds proactively to prevent circumvention of approved drug lists. For competitive athletes subject to WADA testing, BPC-157 use is prohibited and can result in sanctions.
What is the u0022Wolverine Protocolu0022?
The u0022Wolverine Protocolu0022 is an informal term used in some research and athletic communities to describe the combination of BPC-157 with other tissue repair peptides (commonly TB-500) for enhanced recovery from severe injury. The name references the fictional character's rapid healing. The protocol is based on theoretical synergy. However, there is no published data examining BPC-157 and TB-500 combination in any animal model or human population. No clinical evidence supports that combination therapy provides greater benefit than monotherapy, and potential risks of combined peptides are unknown.
What is FDA Category 2 and what does it mean for BPC-157?
FDA Category 2 encompasses novel unapproved compounds that do not meet criteria for expedited pathways (like Breakthrough Therapy designation) but may have merit for standard clinical development. Placing BPC-157 in Category 2 means the FDA does not view it as showing sufficiently compelling preliminary evidence to warrant fast-tracked approval, but development is not prohibited. Category 2 status creates a structural problem — most pharmaceutical development in this category remains underfunded or abandoned because the regulatory pathway is lengthy and uncertain without guaranteed market return.
How does BPC-157 compare to TB-500?
Both are tissue repair peptides with animal evidence for tendon and muscle healing, but they differ mechanistically and in evidence maturity. BPC-157 promotes healing across multiple tissue types via angiogenesis and cell migration. TB-500 (a 43 amino acid fragment of thymosin beta-4) works specifically through actin polymerization. TB-500 has independent replication from multiple laboratories worldwide, while BPC-157 evidence comes predominantly from one research group. Neither has FDA approval. TB-500 is the more independently validated compound; BPC-157 has broader tissue application claims but less robust verification.
Why does most BPC-157 research come from one lab?
Most BPC-157 research originates from the Sikiric laboratory in Zagreb, Croatia, which first isolated and characterized the compound in 1994. This group has published over 100 papers on BPC-157. The concentration reflects intellectual/patent history, funding limitations, technical barriers, and career incentives. The lack of independent replication is not necessarily evidence of fraud, but it represents a structural limitation of the evidence base. For a compound to be considered scientifically validated, independent labs should reproduce key findings. That replication remains sparse for BPC-157.
Are there any human clinical trials of BPC-157?
No large-scale randomized controlled clinical trials have been completed. The human evidence consists of a 2025 intravenous safety pilot (n=20) reporting no serious adverse events, small preliminary studies examining oral administration, and Phase II-equivalent work with limited participant numbers. None of these meet the standard for Phase III efficacy trials. A proper clinical trial for tendon healing would require 50–200 participants per arm, randomized assignment, blinding, and multi-center execution — work that has not been funded or initiated.